Patent intelligence · US
US 10532106
Bicyclic peptide ligands specific for MT1-MMP
Bicyclic peptide ligands specific for MT1-MMP
Patent details — US 10532106
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 14, 2020
- Expiration
- Jan 9, 2040
- Applicant
- BicycleRD Limited
- Claims
- 12
- CPC classes
- A61K, A61K31/195, A61K47/547, A61K47/64
Quick answer
US 10532106 (Bicyclic peptide ligands specific for MT1-MMP) is held by BicycleRD Limited. Status: granted. Granted Jan 14, 2020. Expires Jan 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BicycleRD Limited
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/195, A61K47/547, A61K47/64, A61K51/0482, A61K51/08
More from BicycleRD Limited
Related pharmaceutical patents in our USPTO index.
-
US 12378288
Multimeric bicyclic peptide ligands
granted -
US 12377155
Bicyclic peptide ligands specific for PSMA
granted -
US 12350343
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12318454
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12150998
Bicyclic peptide ligands specific for P-selectin
granted -
US 12049520
Bicyclic peptide ligands specific for CD137
granted -
US 11970555
Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
granted -
US 11970553
Heterotandem bicyclic peptide complex
granted
Frequently asked questions
What is US patent 10532106?
US 10532106 (Bicyclic peptide ligands specific for MT1-MMP) is held by BicycleRD Limited. Status: granted. Granted Jan 14, 2020. Expires Jan 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10532106?
BicycleRD Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 10532106 expire?
Our index shows an expiration date of Jan 9, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.